Advertisement

Topics

Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux

06:26 EDT 8 Aug 2017 | FinanzNachrichten

KENILWORTH (NJ) (dpa-AFX) - Merck KGaA (MKGAY.PK) announced that the National Institute for Health and Care Excellence or NICE for England has issued a positive Final Appraisal Determination or FA...

Original Article: Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux

NEXT ARTICLE

More From BioPortfolio on "Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...